Really? I've always been saying it's all about global expansion and you know my take on Painchek's technology limitation which will make it very hard for them but thought they would get most of the Australian market since APS is the standard here, however, even the uptake has been slow and what other product does Painchek have commercialized since Painchek used clinical data tested on dementia patient to gain regulatory approval? Painface, I'm not too sure as I can't see how they can detect false positive, they proven Painchek is accurate when the infant is under surgery and that's all.
PCK Price at posting:
8.9¢ Sentiment: None Disclosure: Not Held
